OBJECTIVE: Adjuvant intraperitoneal (IP) platinum-based chemotherapy has been shown to improve outcome for patients with advanced ovarian cancer. We hypothesize that patients who have received adjuvant IP chemotherapy more commonly recur first at extraperitoneal sites than patients who have received adjuvant intravenous (IV) chemotherapy. METHODS: Patients with newly diagnosed stage IIIC optimally debulked serous ovarian cancer were identified from institutional databases. Patterns of recurrence were compared between patients who received IV and IP chemotherapy using standard two-sided statistical tests. RESULTS: Of the 104 patients who met inclusion criteria, 60 received IV chemotherapy and 44 received IP chemotherapy. Patients in the IV group had a first recurrence more commonly in the lower abdomen or pelvis than the IP group. Patients in the IP group more commonly recurred in the upper abdomen and extra-abdominal lymph nodes. More patients in the IP group than the IV group recurred at extra-abdominal sites (45.5% versus 23.3%, P=0.018). CONCLUSIONS: Patients receiving adjuvant IP chemotherapy are less likely to first recur in the lower abdomen or pelvis and more likely to recur outside of the abdominal cavity. The data suggest that IP chemotherapy is highly effective in the anatomic areas of peritoneal distribution.
OBJECTIVE: Adjuvant intraperitoneal (IP) platinum-based chemotherapy has been shown to improve outcome for patients with advanced ovarian cancer. We hypothesize that patients who have received adjuvant IP chemotherapy more commonly recur first at extraperitoneal sites than patients who have received adjuvant intravenous (IV) chemotherapy. METHODS:Patients with newly diagnosed stage IIIC optimally debulked serous ovarian cancer were identified from institutional databases. Patterns of recurrence were compared between patients who received IV and IP chemotherapy using standard two-sided statistical tests. RESULTS: Of the 104 patients who met inclusion criteria, 60 received IV chemotherapy and 44 received IP chemotherapy. Patients in the IV group had a first recurrence more commonly in the lower abdomen or pelvis than the IP group. Patients in the IP group more commonly recurred in the upper abdomen and extra-abdominal lymph nodes. More patients in the IP group than the IV group recurred at extra-abdominal sites (45.5% versus 23.3%, P=0.018). CONCLUSIONS:Patients receiving adjuvant IP chemotherapy are less likely to first recur in the lower abdomen or pelvis and more likely to recur outside of the abdominal cavity. The data suggest that IP chemotherapy is highly effective in the anatomic areas of peritoneal distribution.
Authors: Marina Stasenko; Paulina Cybulska; Noah Feit; Vicky Makker; Jason Konner; Roisin E O'Cearbhaill; Kaled M Alektiar; Kathryn Beal; Ginger J Gardner; Kara C Long Roche; Yukio Sonoda; Dennis S Chi; Oliver Zivanovic; Mario M Leitao; Karen A Cadoo; William P Tew Journal: Gynecol Oncol Date: 2019-05-18 Impact factor: 5.482
Authors: Alexi A Wright; Angel Cronin; Dana E Milne; Michael A Bookman; Robert A Burger; David E Cohn; Mihaela C Cristea; Jennifer J Griggs; Nancy L Keating; Charles F Levenback; Gina Mantia-Smaldone; Ursula A Matulonis; Larissa A Meyer; Joyce C Niland; Jane C Weeks; David M O'Malley Journal: J Clin Oncol Date: 2015-08-03 Impact factor: 44.544
Authors: Minh D Dao; Laura M Alwan; Heidi J Gray; Hisham K Tamimi; Barbara A Goff; John B Liao Journal: Gynecol Oncol Date: 2013-04-28 Impact factor: 5.482
Authors: Karen A Cadoo; Rachel N Grisham; Roisin E O'Cearbhaill; Nicole N Boucicaut; Melissa Henson; Alexia Iasonos; Qin Zhou; Debra M Sarasohn; Jacqueline Gallagher; Sara Kravetz; Dmitriy Zamarin; Vicky Makker; Paul J Sabbatini; William P Tew; Carol Aghajanian; Jason A Konner Journal: Gynecol Oncol Date: 2020-01-17 Impact factor: 5.482